NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced the publication from the University of Oxford of promising clinical results and long-term benefits of choroideremia gene therapy in this week’s issue of the New England Journal of Medicine (NEJM). Nightstar is now developing this gene therapy approach and the viral vector known as adeno-associated virus 2 (AAV2) to deliver a copy of the gene encoding Rab-escort protein 1 (REP-1) gene, the mutation of which leads to damage of retinal cells of patients with choroideremia, an inherited form of progressive blindness.
The study enrolled 6 patients with choroideremia at the University of Oxford’s Nuffield Laboratory of Ophthalmology under principal investigator Professor Robert MacLaren. As published in the NEJM, the clinical research findings demonstrated that 5 patients who received the full dose of AAV2-REP1 treatment maintained or improved vision in their treated eye for the extent of post-treatment observation (up to 3.5 years). In two patients, a significant improvement in vision of greater than 3 lines on an eye chart was sustained to the last time point reached. In the untreated eyes, vision declined in 5 out of the 6 patients at 3.5 years.
David Fellows, CEO of Nightstar said: “Our mission is to maintain sight in patients suffering from a range of untreatable blinding diseases and the data published in the NEJM demonstrates that the effects of gene therapy are durable and could provide a single treatment for many types of inherited retinal dystrophies.”
Mr. Fellows continued: “We are continuing to advance our AAV2-REP1 program in clinical trials and concurrently moving forward on two other gene therapy programs for sight threatening diseases in the retina.”
Robert MacLaren, Professor of Ophthalmology at the University of Oxford commented: “Gene therapy has huge potential as a treatment for many patients who are suffering from inherited retinal dystrophies. Although there have recently been questions about the long-term impact of certain gene therapy regimens, we believe we now have strong validation of sustained, long-term efficacy following a single injection of the AAV2-REP1 viral vector.”
Article: Visual Acuity after Retinal Gene Therapy for Choroideremia, Robert E. MacLaren, et al., New England Journal of Medicine, doi: 10.1056/NEJMc1509501, published 27 April 2016.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.